Modulation_NN
of_IN
the_DT
expression_NN
of_IN
the_DT
IFN-gamma_NN
receptor_NN
beta-chain_NN
controls_VBZ
responsiveness_NN
to_TO
IFN-gamma_NN
in_IN
human_JJ
peripheral_JJ
blood_NN
T_NN
cells_NNS
._.

IFN-gamma_NN
has_VBZ
potent_JJ
antiproliferative_JJ
and_CC
apoptotic_JJ
effects_NNS
in_IN
T_NN
cells_NNS
that_IN
are_VBP
important_JJ
in_IN
determining_VBG
T_NN
cell_NN
development_NN
and_CC
polarized_VBN
differentiation_NN
._.

Therefore_RB
,_,
any_DT
event_NN
that_WDT
enables_VBZ
T_NN
cells_NNS
to_TO
become_VB
less_RBR
responsive_JJ
to_TO
IFN-gamma_NN
may_MD
potentially_RB
alter_VB
immune_JJ
responsiveness_NN
to_TO
Ag_NN
._.

In_IN
this_DT
work_NN
,_,
we_PRP
show_VBP
that_IN
human_JJ
peripheral_JJ
blood_NN
T_NN
cells_NNS
that_WDT
are_VBP
stimulated_VBN
through_IN
the_DT
TCR_NN
and_CC
expanded_VBN
with_IN
IL-2_NN
are_VBP
unresponsive_JJ
to_TO
IFN-gamma_NN
,_,
as_IN
determined_VBN
by_IN
a_DT
lack_NN
of_IN
activation_NN
of_IN
jak_NN
kinases_NNS
and_CC
the_DT
transcription_NN
factor_NN
,_,
STAT1_NN
-LRB-_-LRB-
alpha_NN
-RRB-_-RRB-
,_,
a_DT
signal_NN
transducer_NN
and_CC
activator_NN
of_IN
transcription_NN
._.

This_DT
nonresponsiveness_NN
occurs_VBZ
because_IN
of_IN
a_DT
lack_NN
of_IN
expression_NN
of_IN
the_DT
beta-chain_NN
-LRB-_-LRB-
accessory_NN
factor_NN
-RRB-_-RRB-
of_IN
the_DT
IFN-gamma_NN
receptor_NN
,_,
while_IN
at_IN
the_DT
same_JJ
time_NN
maintaining_VBG
IFN-gamma_NN
receptor_NN
alpha-chain_NN
expression_NN
._.

Expression_NN
of_IN
the_DT
beta-chain_NN
can_MD
be_VB
restored_VBN
by_IN
secondary_JJ
TCR_NN
ligation_NN
or_CC
PMA_NN
treatment_NN
._.

T_NN
cell_NN
blasts_NNS
treated_VBN
with_IN
PMA_NN
are_VBP
now_RB
responsive_JJ
to_TO
IFN-gamma_NN
._.

When_WRB
freshly_RB
isolated_VBN
,_,
highly_RB
enriched_VBN
-LRB-_-LRB-
&gt;_JJR
98_CD
%_NN
-RRB-_-RRB-
T_NN
cells_NNS
are_VBP
examined_VBN
for_IN
IFN-gamma_NN
responsiveness_NN
;_:
these_DT
cells_NNS
can_MD
respond_VB
to_TO
IFN-gamma_NN
and_CC
express_VB
beta-chain_NN
._.

Therefore_RB
,_,
as_IN
T_NN
cells_NNS
progress_VBP
from_IN
primary_JJ
TCR_NN
activation_NN
through_IN
IL-2-dependent_JJ
proliferation_NN
,_,
followed_VBN
by_IN
secondary_JJ
TCR_NN
stimulation_NN
,_,
their_PRP$
responsiveness_NN
to_TO
IFN-gamma_NN
varies_VBZ
,_,
and_CC
this_DT
may_MD
affect_VB
their_PRP$
ability_NN
to_TO
participate_VB
in_IN
an_DT
ongoing_JJ
immune_JJ
response_NN
._.

